Phase III results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj. Multi-dose, demonstrate that it ...

Merck and Cidara Therapeutics, Inc., have entered into a definitive agreement under which Merck will acquire Cidara for $9.2 ...

Merck has entered a definitive agreement to acquire Cidara Therapeutics, a biotechnology company developing drug-Fc conjugate ...

The addition of neoadjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved pathologic complete response (pCR) ...

In a significant move to bolster its portfolio, Merck has announced its acquisition of Cidara Therapeutics for nearly $9.2 billion. This deal, which aims to secure access to an ex ...

Hepatitis A's effective, indigenous vaccine warrants urgent inclusion in India's Universal Immunisation Programme.

The vaccine effectiveness of PCV20 against IPD and all-cause pneumonia was highest among individuals aged 65 to 74 years and decreased with increasing age.

PATH and EuBiologics Co., LTD are pleased to announce Phase 3 results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj.® Multi-dose. EuTYPH-C Inj.® ...

Completed the sale of FibroGen China to AstraZeneca for approximately $220 millionInitiated the Phase 2 monotherapy trial of FG-3246, a potential ...

Trastuzumab emtansine is linked to a lower incidence of decrease in left ventricular ejection fraction than other trastuzumab ...

Cidara Therapeutics ( ($CDTX) ) has provided an update. On November 13, 2025, Cidara Therapeutics entered into a merger agreement with Merck, ...

Merck has made several big-ticket deals this year, led by its $10 billion buyout of Verona Pharma in July, giving the pharma ...